Transarterial Chemoembolization Complicated by Deteriorating Hepatic Function

ABSTRACT

Worsening hepatic function is a well-known potential complication of chemoembolization and occurs in up to 58% of patients undergoing chemoembolization. Although liver function returns to baseline levels within 3–4 weeks in the majority of patients, fulminant liver failure and death occur with a reported frequency of ~2–10%. Poor performance status, portal vein obstruction, biliary obstruction, extensive tumor burden, and Child-Pugh status B or C are among factors predisposing to an increased risk of transient or fulminant hepatic failure, with Child-Pugh status being the most accurate. Unless the patient is a candidate for liver transplantation, treatment for hepatic failure is limited to supportive measures.

Chemoembolization - liver failure - complications

REFERENCES

• 1 Hong K, McBride J D, Georgiades C S et al.. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization.  J Vasc Interv Radiol. 2009;  20 (3) 360-367
• 2 Kingham T P, D'Angelica M, Kemeny N E. Role of intra-arterial hepatic chemotherapy in the treatment of colorectal cancer metastases.  J Surg Oncol. 2010;  102 (8) 988-995
• 3 Gee M, Soulen M C. Chemoembolization for hepatic metastases.  Tech Vasc Interv Radiol. 2002;  5 (3) 132-140
• 4 Gonsalves C F, Brown D B. Chemoembolization of hepatic malignancy.  Abdom Imaging. 2009;  34 (5) 557-565
• 5 Liapi E, Georgiades C C, Hong K, Geschwind J F. Transcatheter arterial chemoembolization: current technique and future promise.  Tech Vasc Interv Radiol. 2007;  10 (1) 2-11
• 6 Marelli L, Stigliano R, Triantos C et al.. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.  Cardiovasc Intervent Radiol. 2007;  30 (1) 6-25
• 7 Huang Y S, Chiang J H, Wu J C, Chang F Y, Lee S D. Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test.  Am J Gastroenterol. 2002;  97 (5) 1223-1227
• 8 Kothary N, Weintraub J L, Susman J, Rundback J H. Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk.  J Vasc Interv Radiol. 2007;  18 (12) 1517-1526, quiz 1527
• 9 Georgiades C S, Liapi E, Frangakis C et al.. Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization.  J Vasc Interv Radiol. 2006;  17 (10) 1619-1624
• 10 Chung J W, Park J H, Han J K et al.. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization.  Radiology. 1996;  198 (1) 33-40
• 11 Kiely J M, Rilling W S, Touzios J G et al.. Chemoembolization in patients at high risk: results and complications.  J Vasc Interv Radiol. 2006;  17 (1) 47-53
• 12 Paye F, Farges O, Dahmane M, Vilgrain V, Flejou J F, Belghiti J. Cytolysis following chemoembolization for hepatocellular carcinoma.  Br J Surg. 1999;  86 (2) 176-180